The Use of Glaucarubin (a Crystalline Glycoside Isolated from Simarouba Glauca) in the Treatment of Human Colonic Amebiasis

F. van AssendelftDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by F. van Assendelft in
Current site
Google Scholar
PubMed
Close
,
J. W. MillerDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by J. W. Miller in
Current site
Google Scholar
PubMed
Close
,
D. T. MintzDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by D. T. Mintz in
Current site
Google Scholar
PubMed
Close
,
J. A. SchackDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by J. A. Schack in
Current site
Google Scholar
PubMed
Close
,
P. OttolenghiDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by P. Ottolenghi in
Current site
Google Scholar
PubMed
Close
, and
H. MostDepartment of Preventive Medicine, New York University-Bellevue Medical Center, Tropical Disease Diagnostic Clinic, Lower East Side Health Center, New York City Health Department, New York City

Search for other papers by H. Most in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary

Glaucarubin, a crystalline glycoside isolated from Simarouba glauca and found to have amebicidal properties in vitro and in experimental animal amebiasis, was evaluated in the treatment of the human infection. Cure rates in the order of 70 per cent were observed following treatment by mouth for 10 days with daily doses of 5 mg./kg. (maximum daily dose 300 mg.). With the exception of vomiting in 2 patients and a transitory decrease in leucocyte count in another, the drug was well tolerated in 113 patients.

Save